Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026
Rhea-AI Summary
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman, MD, will present at BIO-Europe Spring 2026 in Lisbon on March 24, 2026, from 1:30-1:45 p.m. WET in the Presentation Theatre A. The presentation will cover the company’s CNS and immunology programs and marketed products.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TNXP
On the day this news was published, TNXP gained 11.13%, reflecting a significant positive market reaction. Argus tracked a peak move of +7.7% during that session. Our momentum scanner triggered 32 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $22M to the company's valuation, bringing the market cap to $216.36M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TNXP was up 10.32% while key biotech peers like NMRA, ANNX, CADL, OMER, and VNDA showed declines between about 2–6%, indicating stock-specific strength rather than a broader peer rally.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Earnings results | Neutral | -1.3% | Reported 2025 financials, TONMYA launch metrics, cash balance, and capital raises. |
| Mar 10 | Clinical data update | Positive | +1.6% | Post hoc Phase 3 TONMYA analyses showing rapid pain relief and strong risk–benefit profile. |
| Mar 09 | Clinical data presentation | Positive | +1.6% | RESILIENT Phase 3 trial data for TONMYA presented at AAPM PainConnect meeting. |
| Mar 05 | PK study publication | Positive | -2.0% | Phase 1 pharmacokinetic results for TONMYA showing rapid absorption and high early exposure. |
| Mar 03 | Conference poster | Positive | +0.3% | Announcement of TONMYA poster on patient-centered outcomes at AAPM PainConnect. |
Recent TNXP news has generally seen modest positive price alignment, with one notable divergence on favorable pharmacokinetic data.
Over the past weeks, Tonix has highlighted commercialization and clinical progress for TONMYA, including Phase 3 data presentations and pharmacokinetic publications, plus 2025 earnings showing net product revenue of $13.1M. Most of these updates led to small positive moves, though the March 5 pharmacokinetic publication coincided with a -1.97% reaction. Today’s BIO-Europe Spring 2026 presentation fits into this pattern of ongoing visibility-building around TONMYA and the broader CNS portfolio.
Regulatory & Risk Context
Tonix has an active S-3/A shelf registration dated 2025-09-04, with a recent 424B5 usage on 2025-11-21. The latest amendment re-filed an auditor consent exhibit and did not modify the prospectus terms, indicating the existing shelf structure remains in place.
Market Pulse Summary
The stock surged +11.1% in the session following this news. A strong positive reaction aligns with Tonix’s pattern of generally constructive responses to visibility and data milestones, as seen around recent TONMYA updates with mostly aligned price moves. However, the stock still traded 79.72% below its 52-week high and below the 200-day MA of 25.57, suggesting prior weakness. An active S-3/A shelf and the company’s ongoing capital needs, as reflected in recent filings, remained factors investors monitored when assessing durability.
Key Terms
sublingual medical
fibromyalgia medical
major depressive disorder medical
acute stress disorder medical
prader-willi syndrome medical
monoclonal antibody medical
cd40 ligand inhibitor medical
prophylaxis medical
AI-generated analysis. Not financial advice.
BERKELEY HEIGHTS, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial biotechnology company, announced today that Seth Lederman, MD, Chief Executive Officer, will deliver a company presentation at BIO-Europe Spring 2026, being held March 23-25, 2026, in Lisbon, Portugal.
Company Presentation Details
Date and Time: Tuesday, March 24, 2026, 1:30-1:45 p.m. WET
Location: Presentation Theatre A
Presenter: Seth Lederman, MD, Chief Executive Officer
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals* is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA® (cyclobenzaprine HCl sublingual tablets 2.8 mg), is the first new treatment for fibromyalgia in adults in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® Symtouch® (sumatriptan injection 3 mg) and Tosymra® (sumatriptan nasal spray 10 mg). Tonix is investigating TONMYA® in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. To learn more, visit www.tonixpharma.com and follow the Company on LinkedIn and X.
*Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. TONMYA is a registered trademark of Tonix Pharma Limited. All other marks are property of their respective owners.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 12, 2026, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor Contacts
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599
Brian Korb
astr partners
(917) 653-5122
brian.korb@astrpartners.com
Media Contacts
Deborah Elson
Tonix Pharmaceuticals
deborah.elson@tonixpharma.com
Ray Jordan
Putnam Insights
ray@putnaminsights.com
